Home Infusion Therapy Industry

The global home infusion therapy market was valued at USD 35.96 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 8.1% from 2024 to 2030. Home infusion therapy refers to the delivery of therapeutic treatments, medications, or fluids directly into a patient’s bloodstream through intravenous (IV) infusion, typically in the convenience of their own home. This method of treatment is becoming increasingly popular due to several key factors. One major driver is the expanding geriatric population, which is often characterized by limited mobility and a preference for receiving care at home. Additionally, technological advancements are making home infusion therapy safer and more efficient.

Infusion therapy, including IV therapy and IV hydration therapy, is critical in treating conditions such as immune deficiencies, cancer, and congestive heart failure, where oral medications are not effective. As long-term treatment becomes more common for many patients, home infusion therapy has emerged as a cost-effective alternative to hospital-based care. The use of IV therapy and IV hydration therapy allows patients to access effective, personalized medical solutions in the comfort of their homes, further driving market growth.

The COVID-19 pandemic had a significant impact on the home infusion therapy market, with the therapy becoming a vital necessity as healthcare facilities were overwhelmed with COVID-19 patients. Despite operational challenges and supply chain disruptions caused by regional and nationwide lockdowns, the market saw substantial growth in 2020. For instance, Medtech Dive reported that Baxter’s third-quarter sales in 2020 reached USD 2.97 billion, reflecting a 4% growth due to the increasing demand for COVID-related medical products. By Q3 2021, Baxter’s operational sales had grown by 6%, reaching USD 3.2 billion compared to USD 3.0 billion in Q3 2020, highlighting the market’s recovery and continued growth post-pandemic.

Gather more insights about the market drivers, restrains and growth of the Home Infusion Therapy Market

Application Insights

The anti-infective segment led the home infusion therapy market in 2023, capturing a revenue share exceeding 26.9%, due to:

• A high number of procedures performed to administer antifungal and antibiotic drugs, underscoring the growing need for anti-infective treatments in a home setting.
• The use of anti-infective therapy at home provides a significant advantage by reducing patients' exposure to hospital-acquired infections (HAIs), which are a risk in clinical settings, especially for immunocompromised patients.

The chemotherapy segment is projected to be the fastest-growing segment over the forecast period, driven by:

• The rising prevalence of cancer, which is increasing demand for home-based chemotherapy solutions, offering more comfort and flexibility to patients.
• Compact and continuous pressure pumps used in home chemotherapy that allow for extended use without batteries, making them convenient for prolonged therapy.
• These pumps enable precise administration of chemotherapy drugs, ensuring the right infusion speed and dosage to maximize therapeutic efficacy and patient safety in a home environment.

Order a free sample PDF of the Home Infusion Therapy Market Intelligence Study, published by Grand View Research.

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Contact:

Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc.

Phone: 1-415-349-0058

Toll Free: 1-888-202-9519

Email: sales@grandviewresearch.com

Web: https://www.grandviewresearch.com/

Follow Us: LinkedIn | Twitter